Down syndrome (trisomy 21) is the most common genetic cause of intellectual disability. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer's disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glaucoma is a group of optic neuropathies and the world's leading cause of irreversible blindness. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common form of cognitive decline worldwide, occurring in about 10% of people older than 65 years. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The vast majority of CAA remains sporadic, with increasing prevalence with age and very frequent coexistence with Alzheimer’s disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 85 patients were enrolled; 28 (32.9%) were classified as NECPAL-positive and 57 (67.1%) as NECPAL-negative. 5 key findings →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In neurodegenerative diseases, microglia-mediated neuroinflammation and oxidative stress are central events. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Statins show mixed results in CKD and ESRD, with limited benefits in reducing cardiovascular events in dialysis patients. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia is a growing problem of global relevance, currently affecting over 55 million people worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 747 studies identified, 6 studies fulfilled the eligibility criterion for this review. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Due to the lack of pharmacological treatment for dementia, timely detection of subjects at risk can be of seminal importance for preemptive rehabilitation interventions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Black/African American (AA) individuals have a higher risk of Alzheimer's disease (AD) than White non-Hispanic persons of European ancestry (EUR) for reasons that may include economic disparities, cardiovascular health, quality of education, and biases in the methods used to diagnose AD. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is often comorbid with other pathologies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The CSF level of Ng was significantly higher, whereas the NPTXR was significantly lower in the AD patients than in cognitively healthy controls. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
41/100
Considering the overall sci-entific evidence presented, it is important to note that GLPs are no longer just antihyperglycemic drugs but are remarkably versatile, with a future in almost every field of medicine. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CAD did not differ across biomarker groups (Kruskal–Wallis H(2) = 0.17, p = 0.91). 5 key findings →
Participants: 140 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Patients with hearing impairment presented slightly altered results on cognitive tests, typical of a mild cognitive impairment. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Specific health plans for DS and conducting clinical and translational research on the challenges of aging, including AD, are necessary and feasible. 1 key finding →
Participants: 114 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Retinal microcirculation shares similar features with cerebral small blood vessels. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obstructive sleep apnea (OSA) is a prevalent disorder characterized by recurrent upper airway obstruction during sleep resulting in intermittent hypoxemia and sleep fragmentation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD), the most common cause of dementia, is a neurodegenerative disease that seriously threatens human health and life quality. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most prevalent cause of dementia and can be conceptualized as a tauopathy initiated by the accumulation of amyloid-β (Aβ) in the brain. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This narrative review of Alzheimer's disease (AD) history, therapy and prevention shows that its conceptualization has changed three times over 100 years. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (trisomy 21) is the most common genetic cause of intellectual disability. 1 key finding →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →